Sarepta Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Pmo Products at $230.6 million, 70% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,399
|
329
|
331
|
370
|
399
|
513
|
612
|
638
|
467
|
| Pmo Products |
957
-1.4%
share 68.4%
|
231
-0.3%
share 70.1%
|
229
-3.4%
share 69.1%
|
259
+2.0%
share 70.1%
|
239
-4.1%
share 59.7%
|
231
share 45.1%
|
237
share 38.7%
|
254
share 39.8%
|
249
share 53.3%
|
| Elevidys |
442
-63.8%
share 31.6%
|
98
-65.2%
share 29.9%
|
102
-72.8%
share 30.9%
|
110
-71.3%
share 29.9%
|
131
-27.3%
share 32.9%
|
282
share 54.9%
|
375
share 61.3%
|
384
share 60.2%
|
181
share 38.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SRPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 873303
- Former names
- Sarepta Therapeutics, Inc. (until Nov 5, 2026); AVI BIOPHARMA INC (until Jul 12, 2012); ANTIVIRALS INC (until May 12, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.